Cargando…
Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease
Certolizumab pegol (CZP), an anti–tumor necrosis factor α agent, is an effective therapy for Crohn's disease (CD). A population pharmacokinetic (PK) analysis of subcutaneously administered CZP was performed using data from 2157 CD patients from 9 separate studies. The aim was to determine which...
Autores principales: | Wade, Janet R., Parker, Gerry, Kosutic, Gordana, Feagen, Brian G., Sandborn, William J., Laveille, Christian, Oliver, Ruth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6680228/ https://www.ncbi.nlm.nih.gov/pubmed/25735646 http://dx.doi.org/10.1002/jcph.491 |
Ejemplares similares
-
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2017) -
Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
por: Vande Casteele, N., et al.
Publicado: (2017) -
Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015) -
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021) -
Population pharmacokinetics of tenofovir and tenofovir‐diphosphate in healthy women
por: Burns, Rebecca N., et al.
Publicado: (2015)